Proteome Sciences PLC Director/PDMR Shareholding (0670I)

TIDMPRM

RNS Number : 0670I

Proteome Sciences PLC

21 November 2018

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director/PDMR Shareholding

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 19 November 2018 it purchased 500,000 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.42p per Ordinary Share (the "Purchase"). Following the purchase, Vulpes has a total direct and indirect interest in 63,446,734 equivalent to 21.49% of Proteome Sciences' total issued share capital.

The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes Investment Management and the Company, he now has an interest in 63,446,734 Ordinary Shares of the Company representing 21.49% of the issued share capital of the Company.

The below notification is made in accordance with the requirements of the EU Market Abuse regulation.

 
 1.   Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name:                                      Martin Diggle 
     -----------------------------------------  -------------------------------- 
      Reason for the notification 
     --------------------------------------------------------------------------- 
 a)   Position/status:                           Non-Executive Director 
     -----------------------------------------  -------------------------------- 
 b)   Initial notification/Amendment:            Initial Notification 
     -----------------------------------------  -------------------------------- 
      Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     --------------------------------------------------------------------------- 
 a)   Name:                                      Proteome Sciences Plc 
     -----------------------------------------  -------------------------------- 
 b)   LEI:                                       213800Q62ICXANKU2986 
     -----------------------------------------  -------------------------------- 
      Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     --------------------------------------------------------------------------- 
 a)   Description of the financial instrument,   Ordinary Shares of 1p nominal 
       type of instrument:                        value 
       Identification code:                       GB0003104196 
     -----------------------------------------  -------------------------------- 
 b)   Nature of the transaction:                 Purchase of Ordinary Shares 
     -----------------------------------------  -------------------------------- 
 c)   Price(s) and volume(s):                      Price(s)   Volume(s) 
                                                    3.42       500,000 
                                                              ---------- 
     -----------------------------------------  -------------------------------- 
 d)   Aggregated information:                    Single transaction as in 
        *    Aggregated volume:                   4 c) above Average   Volume(s) 
                                                    Price 
                                                   3.42      500,000 
        *    Price:                                         ---------- 
     -----------------------------------------  -------------------------------- 
 e)   Date of the transaction:                   19 November 2018 
     -----------------------------------------  -------------------------------- 
 f)   Place of the transaction:                  London Stock Exchange, 
                                                  AIM (XLON) 
     -----------------------------------------  --------------------------------

For further information:

 
 Proteome Sciences plc 
 Dr Jeremy Haigh, Chief Executive        Tel: +44 (0)20 7043 2116 
  Officer 
 Dr Ian Pike, Chief Scientific Officer 
  Richard Dennis, Chief Commercial 
  Officer 
 
 finnCap Limited (Nominated Adviser & Broker) 
 Geoff Nash/Hannah Boros (Corporate      Tel: +44 (0)20 7220 0500 
  Finance) 
  Tim Redfern (Broking)

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) ) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator(TM) ). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHFEWSUFFASEDF

(END) Dow Jones Newswires

November 21, 2018 04:41 ET (09:41 GMT)

Proteome Sciences (AQSE:PRM.GB)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025